- A. Health Biotechnology
- Areas of activity
- Gene Therapy
- Therapeutic areas
- Blood and lymphatic system
- Digestive system and hepatology
VCN Biosciences mission is the development of new agents for the treatment of cancer based on oncolytic adenoviruses with high potency and selectivity. The company develops new candidate viruses from its design, preclinical studies, and early efficacy studies in humans (Phase I and II clinical trials).
VCN Biosciences SL is a company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells.
The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time.
These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas or melanoma, which are some of the current tumor targets of VCN Biosciences.